1. REDUCED INTENSITY (FB2) VS REDUCED TOXICITY MYELOABLATIVE (FB3‐4) FLUDARABINE/BUSULFAN‐BASED CONDITIONING REGIMENS FOR NON‐HODGKIN LYMPHOMA (NHL) ALLOGRAFTED PATIENTS. (June 2017) Authors: Le Bourgeois, A.; Labopin, M.; Blaise, D.; Ceballos, P.; Vigouroux, S.; Peffault De Latour, R.; Suarez, F.; Bulabois, C.; Bay, J.; Chantepie, S.; Deconinck, E.; Daguindau, E.; Contentin, N.; Yakoub‐Agha, I.; Cornillon, J.; Francois, S.; Turlure, P.; Charbonnier, A.; Rohrlich, P.; N'Guyen, S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 193 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A new matrikine‐derived peptide up‐regulates longevity genes for improving extracellular matrix architecture and connections of dermal cell with its matrix. (11th November 2019) Authors: Leroux, R.; Ringenbach, C.; Marchand, T.; Peschard, O.; Mondon, P.; Criton, P. Journal: International journal of cosmetic science Issue: Volume 42:Number 1(2020) Page Start: 53 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗